DendriMed scientist seeks to fast-track success

March 30, 2008

Gleaning critical technical knowledge and building important international relationships is top of the agenda for rising Australian biotechnology star, DendriMed Research Director Dr Raisa Monteiro, when she meets with leading industry figures in the US in June.

One of two Australian life scientists chosen from a highly competitive field of candidates for the prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro will attend the world's largest biotechnology meeting, the Biotechnology Industry Organisation (BIO) convention, which attracts over 22,000 delegates from around the globe.

A tailored program of meetings will also be scheduled for her with leading American players including venture capital firms, research institutes, biotechnology entrepreneurs and biopharmaceutical companies, to help build valuable international networks, knowledge and collaborations.

The Advancing BioBusiness Award is an innovative scheme by Merck Sharp & Dohme and Advance, a dynamic, diverse global community of Australian professionals overseas committed to advancing Australia and Australians.

Russian-born Dr Monteiro, whose late father worked with the team that successfully cloned 'Dolly the sheep', is one of Australia's brightest hopes in biotechnology, having moved here in 2002 with her Australian husband, an academic at the University of Queensland. During her 10-year career as a polymer scientist in America and Australia, she has notched up seven US patents with another three applications pending for technology she conceived and developed.

Now at DendriMed, her focus has turned to using smart polymer-based nanostructures to deliver drugs to targeted tissue and organs.

Dr Monteiro said through the Advancing BioBusiness Award, she wants to overcome the tyranny of distance and open up business opportunities in the global marketplace by meeting face-to-face with US biopharmaceutical heavyweights.

"Successfully commercialising Australian technologies is not just about the merit of your science, but also knowing the right people," Dr Monteiro said. "Networking with major players in the US makes distances shorter and bridges easier to cross."

Senator Kim Carr, Minister for Innovation, Industry, Science and Research, said:

"The Advancing BioBusiness Award complements the Rudd Government's policy of promoting innovation and commercialisation in the biotechnology and pharmaceutical sector, encouraging closer links between Australian biotech and global pharmaceutical companies, and helping Australian biotechs access global supply chains."

Dr Phil Kearney, Merck Sharp & Dohme's manager for external scientific affairs, said Australia is recognised for its excellence in medical research and its vigorous and creative biotechnology industry. However the number of drug development projects which reach advanced clinical development is only a quarter of what would be predicted on the basis of our output in scientific literature.

"By immersing two of our top biotechnology people in successful commercial research centres in the United States, and providing them with opportunities to share their learning back at home, we aim to build a stronger Australian capability to win in this highly competitive global knowledge market," he said.

The other recipient of the 2008 Advancing BioBusiness Award is Dr Christopher Wraight, Research Director, Antisense Therapeutics Ltd.
-end-


Research Australia

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.